louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00614757: Insulin Resistance Study
Official title: The Prevalence of Insulin Resistance and the Potential Modulation of Insulin Resistance by N-acetylcysteine (NAC) in Patients Chronically Infected by the Hepatitis C Virus
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Insulin Resistance
Metabolic Syndrome x
Lead sponsor: Midwest Veterans' Biomedical Research Foundation
Sponsor class: OTHER
First posted: 2008-02-13
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate how often patients with hepatitis C infection have abnormalities of sugar and fat utilization. Additionally we would like to find out if these abnormalities of sugar and fat utilization are common in other liver diseases, or related to being overweight.


Eligibility criteria: Inclusion Criteria:

* Ability to give written consent
* HCV RNA PCR positive for 6 months
* Normal Hgb, WBC,Neutrophils
* Platelets of \>/= 65,000
* Direct Bili, within 20% ULN
* Albumin \>3
* Serum Creatinine \<20% ULN
* TSH WNL
* AFP \</= 100

Exclusion Criteria:

* Women who are pregnant or breast-feeding
* No Thiazolidinedione, Metformin,unless required for the treatment of type II DM
* Hepatitis C of non-genotype 1,2,3
* Any other cause for liver disease other than chronic hepatitis C
* Hemoglobinopathies
* Evidence of advanced liver disease
* Previous organ transplant
* Severe psychiatric disorder
* Significant cardiovascular dysfunction within the past 12 months
* Poorly controlled diabetes mellitus
* Immunologically mediated disease
* Any medical condition requiring chronic systemic administration of steroids
* Evidence of an active or suspected cancer
* Substance abuse at the time of the study
* Known HIV
* Irritability or unwillingness to provide informed consent

Primary outcomes:
measure: Those patients who are identified to have insulin resistance will be asked to participate in the treatment phase of the study
timeFrame: 2 years
Secondary outcomes:
measure: One half of patients with insulin resistance will undergo 30 day treatment with N-acetylcysteine to see if we can measure an improvement in fasting insulin and glucose levels
timeFrame: 2 years
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Kansas City VA Medical Center
state: Missouri
Study officials:
affiliation: Kansas City VA Medical Center
name: Prashant K Pandya, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02654457: Identification and Semi-Quantification of Ki-67 Protein Expression Status
Official title: Identification and Semi-Quantification of Ki-67 Protein Expression Status in Formalin Fixed, Paraffin-embedded Normal and Neoplastic Breast Tissue
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: Immunohistochemical
Ki-67
Breast cancer
IHC
Lead sponsor: Applied Spectral Imaging Ltd.
Sponsor class: INDUSTRY
First posted: 2016-01-13
Enrollment: 3
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women having breast cancer aged 21 and up

Brief summary: The purpose of the study is the identification and semi-quantification of Ki-67 protein expression level in breast cancer tissues by the GenASIs GoPth system as compared to manual reading of the same slides.

The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classifying ER/PR IHC stained samples

Detailed description: The anti Ki-67 is a semi-quantitative immunohistochemical (IHC) assay to identify the Ki-67 protein expressions in formalin-fixed, paraffin-embedded human breast cancer tissue specimens. Results from the Ki-67 test is indicated as an aid in the assessment of the protein status of breast cancer patients. While the p53 kit provides the antibody that offer direct visualization and semi-quantification of the protein expression through a brightfield microscope, the GenASIs GoPath system is designed to complement the routine workflow of the pathologist in the analysis and review of immunohistochemically stained histologic slides.

Eligibility criteria: Inclusion Criteria:

* Slides with nuclear borders of tumor nuclei that is distinguishable, and having good integrity.

Exclusion Criteria:

* Slides that have lots of background that interfere with the analysis

Primary outcomes:
measure: IVD study of Ki67 IHC samples: Accuracy of analysis
timeFrame: 1 Day
measure: IVD study of Ki67 IHC samples: Repeatability & Reproducibility of analysis
timeFrame: 1 Day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00425126: Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
Official title: Effect of Procrit(Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Delayed Graft Function
Keywords: Delayed Graft Function
Kidney Transplantation
Lead sponsor: West Penn Allegheny Health System
Sponsor class: OTHER
First posted: 2007-01-22
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Delayed graft function (DGF) is a major complication following deceased donor renal transplantation. The surgical procedure of harvesting a kidney from a cadaveric donor and implanting the kidney into the recipient inevitably causes some amount of injury. While not always clinically significant, anywhere from 10-50% of transplant patients may develop DGF. Ongoing research in animal models has demonstrated benefit with administration of erythropoietin. The investigators propose to study the effect of Procrit(Epoetin Alfa) on delayed graft function in subjects undergoing kidney transplantation.


Eligibility criteria: Inclusion Criteria:

* Patients presenting for kidney transplantation
* Age \> 18
* Deceased donor kidney transplant

Exclusion Criteria:

* History of thrombosis or hypercoagulable state
* Receiving Coumadin or Heparin
* Hemoglobin \>=14 g/dl
* Uncontrolled hypertension

Primary outcomes:
measure: Decrease in Delayed Graft Function
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Allegheny General Hospital
state: Pennsylvania
Study officials:
affiliation: West Penn Allegheny Health System
name: Richard J Marcus, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol. 2012 Sep;7(9):1498-506. doi: 10.2215/CJN.01360212. Epub 2012 Jun 28.
Clinical trial NCT01159626: Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects
Official title: A Phase 1, Randomized, Subject- and Investigator-blind, Sponsor-open, Placebo-controlled, Single- and Multiple-dose Escalation Study to Investigate the Pharmacokinetics, Safety and Tolerability of PF-03463275 in Healthy Male Japanese and Western Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Phase1
Pharmacokinetics
Healthy Male
Japanese
Schizophrenia
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2010-07-09
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This Phase 1 study is the first clinical trial in Japanese subjects. The study is designed to evaluate the single- and multiple-dose pharmacokinetics, safety and tolerability of PF-03463275 oral controlled release formulation in Japanese and Western male subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects between the ages of 18 and 55 years.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2, and a total body weight \>50 kg (110 lbs).
* Japanese subjects must have four Japanese grandparents who were born in Japan.

Exclusion Criteria:

* Subjects that are genotyped to be PM (poor metabolizer), UM (ultrarapid metabolizer), IM/EM and EM/UM for CYP2D6 status.
* Evidence or history of clinically significant hematological (including anemia), renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Primary outcomes:
measure: Adverse events monitoring
timeFrame: Day 0 to Day 4 in each period of Cohort A, Day 0 to Day 10 in Cohort B
measure: Vital signs, ECGs, clinical laboratory tests, clinical evaluations and examinations, suicidality assessment
timeFrame: Screening and Day 0 to Day 4 in each period of Cohort A, Screening and Day 0 to Day 10 in Cohort B
measure: Serum (after single dose): Cmax, AUClast, AUCtau (Calculated only in Cohort B) and as data permit Tmax, AUCinf, t1/2
timeFrame: Day 1 to Day 4 in each period of Cohort A, Day 1 in Cohort B
measure: Serum (after multiple dose): Ctrough, Cmax*, AUCtau* and as data permit Tmax*, t1/2* and Rac* (accumulation ratio) * Calculated only after the last administration.
timeFrame: Day 2 to Day 10 in Cohort B
Secondary outcomes:
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Pfizer Investigational Site
state: California
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT03420326: The Relationship Between Atrial Fibrillation and Frailty in Community-Dwelling Elderly
Official title: The Relationship Between Atrial Fibrillation and Frailty in Community-Dwelling
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Frail Elderly Syndrome
Keywords: Atrial Fibrillation
Frailty status
Body composition
Sarcopenia
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2018-02-05
Enrollment: 256
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: National Taiwan University Hospital Communities in Taipei city

Brief summary: Atrial fibrillation (AF) is the most common arrhythmias in clinical practice. Research investigating hospitalized patients have indicated there are deleterious effects of AF on patients besides the disease burden itself, including longer stay days for hospitalization, higher rates of frailty and increasing mortality rate after discharged in six months. In the community-dwelling research also found that elderly with AF have lower cognitive function, physical functional tests score and slower walking speed compared with the health ones. However, there is limited articles investigating the impact of AF on community-dwelling elderly, and the relationship between AF and frailty is also lack of discussion. According to the aged society and increasing prevalence of AF, the relationship between AF and frailty in community-dwelling elderly is warranting investigated.


Eligibility criteria: Inclusion Criteria:

* Older than 65 years old

Exclusion Criteria:

diagnosed with the following disease

1. Cardiovascular diseases: myocardial infarction, peripheral vascular diseases, aortic plaque
2. Cerebrovascular disease: stroke, transient ischemic attack, emboli
3. Heart failure
4. Participants who cannot finish the trial

Primary outcomes:
measure: Frailty status
timeFrame: The frail status assessment would take about 10 minutes
Secondary outcomes:
measure: Body composition
timeFrame: The body composition test would take about 10 minutes
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Ming-Ting Yang
state: Zhongzheng District
Study officials:
affiliation: College of medicine, National Taiwan University
name: Meng-Yueh Chien
role: STUDY_CHAIR
References:
Clinical trial NCT04891926: Hormonal Influences on Diuresis
Official title: Influence of Hormonale Changes on Diuresis and LUTS in the Gynaecological Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nocturia
Menopause
LUTS
Diuresis
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2021-05-19
Enrollment: 70
Sex: FEMALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study was to observe the effect of hormonal treatment (oral or transdermal substitution therapy) on diuresis (salt and water diuresis) and lower urinary tract symptoms (LUTS) in postmenopausal women


Eligibility criteria: Inclusion Criteria:

* Patients in a postmenopausal state wo wanted to start treatment for menopausal symptoms (hot flushes etc)

Exclusion Criteria:

-

Primary outcomes:
measure: Change of HT on nocturnal frequency
timeFrame: 6 months
Secondary outcomes:
measure: Effect on nocturnal urine production
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
citation: Pauwaert K, Bruneel E, Van Laecke E, Depypere H, Everaert K, Goessaert AS. Does hormonal therapy affect the bladder or the kidney in postmenopausal women with and without nocturnal polyuria: Results of a pilot trial? Maturitas. 2022 Jun;160:61-67. doi: 10.1016/j.maturitas.2022.01.009. Epub 2022 Jan 29.
Clinical trial NCT00976326: A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function
Official title: A Trial Investigating the Pharmacokinetic and Safety Profiles of NN1250 in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment and in Subjects With Normal Hepatic Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes
Healthy
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2009-09-14
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial was conducted in Europe. The aim of this clinical trial was to evaluate if the pharmacokinetic and safety profiles of NN1250 (insulin degludec) are altered to such an extent that the dose should be adjusted in subjects with impaired liver function compared to the dose for subjects with normal liver function.


Eligibility criteria: Inclusion Criteria:

* Subject with normal hepatic function, liver parameters within normal range. Not assessed with the Child-Pugh criteria. Or: Subject with stable hepatic impairment classified as Child-Pugh grade A, B or C as assessed by Investigator
* Body mass index maximum 40.0 kg/m\^2

Exclusion Criteria:

* Subject with any disease or condition which the Investigator feels would interfere with the trial outcome or execution except for conditions associated with hepatic impairment in the group of subjects with compromised hepatic function
* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
* Not able or willing to refrain from smoking during the inpatient period

Primary outcomes:
measure: Area under the NN1250 concentration-time curve after single-dose
timeFrame: from 0 to 120 hours
Secondary outcomes:
measure: Maximum observed NN1250 concentration after single-dose
timeFrame: from 0 to 120 hours
measure: Renal clearance of NN1250
timeFrame: from 0 to 24 hours
measure: Number of adverse events
timeFrame: from Visit 2, Day -1 until Follow-up Visit
Other outcomes:
Locations:
city: Bratislava
country: Slovakia
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Kupcova V, Arold G, Roepstorff C, Hojbjerre M, Klim S, Haahr H. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig. 2014 Feb;34(2):127-33. doi: 10.1007/s40261-013-0154-1.
Clinical trial NCT03663426: Impact of Opioid Free Anesthesia on Outcome After Hip Arthroplasty by Direct Anterior Approach.
Official title: Randomized Controlled Trial Study in Hip Arthroplasty by Direct Anterior Approach Using Opioid Free Anesthesia (OFA) Versus Standard Opioid Anesthesia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hip Arthropathy
Lead sponsor: AZ Sint-Jan AV
Sponsor class: OTHER
First posted: 2018-09-10
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: all patients with a first anterior arthroplasty, give their informed consent to be randomized to control or study protocol.

control means no high steroid dose, opioids for anesthesia; paracetamol, NSAIDs and opioids as analgesia.

study protocol means methylprednisolone 125 mg and opioid free anesthesia followed by paracetamol, NSAIDs and if needed opioids as escape.

Detailed description: study group means for Anesthesia:

1. High dose corticoids pre-operative: 125 mg Methylprednisolone. (Medrol) pre incision and 24h postoperative
2. OFA using a multimodal approach including alpha2agonists, lidocaine and low dose ketamine (max 1mg/kg).
3. Avoid opioids post-operative by using multimodal non-opioid analgesics after OFA. Avoid epidural to allow rapid mobilization.

all patients get Tranexamic acid 1 g (2 amp Exacyl 500mg) before and 1 g after surgery. It act as antifibrinolytic to reduce postoperative bleeding. (reversibly binding to lysine receptor sites on plasminogen) Try to give Continuous deep neuromuscular block (NMB) with a post titanic count (PTC) \< 3 by continuous infusion and monitoring of NMB.

Intravenous Fluid restrictions to 1 ml/kg/h as long as pulse pressure (or plethysmograph) variation \< 20% to reduce wound edema.

The pericapsular injections of local anesthetic, provided the patient had no contraindications such as poor renal function or allergies. 100 ml Ropivacaine 0,2% (max dose 3 mg/kg) + additives (Adrenaline 2,5 cc) (Ropivacaine: max 3 mg/kg)

Eligibility criteria: Inclusion Criteria:

* arthroplasty by anterior approach

Exclusion Criteria:

* allergy or impossible to use any of the drugs included
* revision procedure
* major cardiovascular, pulmonary or renal insufficiency requiring planned post operative intensive care admission

Primary outcomes:
measure: QoR15
timeFrame: measured at 24 hours after surgery.
measure: opioids postoperative
timeFrame: measured at 24 hours after surgery.
measure: CRP
timeFrame: measured at 24 hours after surgery.
Secondary outcomes:
measure: surgical condition
timeFrame: after surgery
measure: muscle damage
timeFrame: after surgery
measure: length of hospital stay
timeFrame: until hospital discharge, maximum 7 days after surgery.
measure: complications
timeFrame: 2 weeks postoperative
Other outcomes:
Locations:
city: Brugge
country: Belgium
facility: Azsintjan
Study officials:
affiliation: AZSint Jan AV
name: Marco Lanckneus, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03331926: Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease
Official title: Collagenase Clostridium Histolytic is a Common Treatment of MCP and PIP Joint Contractures in Dupuytren Disease. A 1 to 4 Year Followup Study of 198 Joints
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dupuytren Contracture
Lead sponsor: Horsens Hospital
Sponsor class: OTHER
First posted: 2017-11-06
Enrollment: 199
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who received Xiapex treatment in Horsens from 2013 to May 2016 with a least 1 years of followup.

Brief summary: To evaluate the effect of collagenase clostridium histolyticum treatment at the Department of Orthopaedic surgery at Horsens Regional Hospital after minimum one-year follow-up (FU).


Eligibility criteria: Inclusion Criteria:

* dupuytrens disease
* xiapex treatment

Exclusion Criteria:

- demens/other psychiatric diseases

Primary outcomes:
measure: Change in extension deficit from baseline to FU in MCP and PIP joints after treatment
timeFrame: Minimum one year after treatment
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Regionshospitalet Horsens
name: Charlotte Hartig-Andreasen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hartig-Andreasen C, Schroll L, Lange J. Clostridium histolyticum as first-line treatment of Dupuytren's disease. Dan Med J. 2019 Feb;66(2):A5527.
Clinical trial NCT06555926: Effect of Acupressure on Carpal Tunnel Syndrome in Pregnant Women
Official title: Effect of Acupressure on Carpal Tunnel Syndrome in Pregnant Women
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Carpal Tunnel Syndrome
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-08-15
Enrollment: 50
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be conducted to investigate the effect of acupressure on carpal tunnel syndrome in pregnant women.

Detailed description: The pregnant women are more prone to develop carpal tunnel syndrome because they retain more fluid during the later stages of their pregnancies. The more fluid retained , the more swelling occurs , squeezing the nerves that run through the hand and finger. Also most women who experience pain, numbness and tingling in the hand for the first time due to pregnancy have no idea that they have carpal tunnel syndrome.

Given the importance of treating CTS and preventing the limitations caused by this syndrome, and since it can turn into a debilitating disease if left untreated, acupressure can be recommended as a safe and noninvasive technique for reducing the severity of clinical symptoms.

Till now, there is no previous studies explored the effect of acupressure on carpal tunnel syndrome in pregnant women. So, this study will be conducted to provide new information about the efficacy of acupressure in management of carpal tunnel syndrome in pregnant women, which will help such pregnant women to overcome this problem and will add new evidence to the field of physical therapy.

Eligibility criteria: Inclusion Criteria:

* Pregnant women who are clinically diagnosed as having carpal tunnel syndrome .
* Their age will be ranged from 20 to 35years old.
* Their body mass index will not exceed 30kg/m2.
* All of them are in their 3rd trimester of pregnancy.(28-40weeks)
* All of them suffer from mild and moderate CTS.
* Degree of carpal tunnel pain will be 2 or more on Visual Analogue scale.

Exclusion Criteria:

* Dermatological abnormalities in the skin of acupionts.
* Internal fixation at the area of acupressure application.
* Smokers .
* Metabolic diseases such as Diabetes mellitus.
* Females who had history of fracture or trauma to the hand .

Primary outcomes:
measure: Assessment of pain severity
timeFrame: 12 weeks
measure: median nerve conduction study
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Cairo University
name: Azza Nashed, professor
role: STUDY_CHAIR
References: